Enhancement of murine phenytoin teratogenicity by the gamma‐glutamylcysteine synthetase inhibitor L‐buthionine‐(S, R)‐sulfoximine and by the glutathione depletor diethyl maleate
- 1 August 1989
- journal article
- research article
- Published by Wiley in Teratology
- Vol. 40 (2) , 127-141
- https://doi.org/10.1002/tera.1420400206
Abstract
The teratogenicity of phenytoin may result from its enzymatic bioactivation to a reactive intermediate, which, if not detoxified, can interact with embryonic tissues and alter development. Glutathione (GSH) is an important cofactor/substrate for many physiological processes and for the detoxification of xenobiotic reactive intermediates. This study examined the effects of the GSH depletor diethyl maleate (DEM) and the GSH synthesis inhibitor L-buthionine-(S,R)-sulfoximine (BSO) on phenytoin embryopathy. Phenytoin, 55 mg/kg, was administered intraperitoneally (ip) to pregnant CD-1 mice at 0900 hr on gestational days 12 and 13. Pretreatment with DEM, 150 or 300 mg/kg ip, enhanced the incidence of phenytoin-induced cleft palates by 3.3-fold and 2.3-fold, respectively (P < 0.05), without affecting the incidence of resorptions, postpartum death, or mean fetal weight. BSO, 1,800 mg/kg ip, given 0.5 hr prior to phenytoin, resulted in a 2.4-fold increase in postpartum lethality and a 5-fold increase in fetal weight loss (P < 0.05), without altering the incidence of resorptions or cleft palates. In two subsequent studies, BSO, 680–1,018 mg/kg/day, was given in the drinking water on gestational days 9 to 13 in the first study and on days 10 to 14 in the second study. Phenytoin, 55 mg/kg ip, was given on days 11 and 12 and on days 11 to 13 in the respective studies. In the first drinking water study, BSO enhanced the incidence of phenytion-induced fetal resorptions 3.8-fold and cleft palates 3.3-fold (P < 0.05) but did not affect postpartum death. In the second study, BSO enhanced the incidence of resorptions, cleft palates, and postpartum death by 2-fold, 2.6-fold, and 1.7-fold, respectively (P < 0.05). In both of the latter two studies, phenytoin-induced fetal weight loss was altered by BSO treatment (P < 0.05). BSO alone had no embryopathic effects. These results suggest that GSH may be involved in the detoxification of a reactive intermediate of phenytion and/or in fetal cytoprotection.Keywords
This publication has 41 references indexed in Scilit:
- Effects of the tumor promoter 12-O-tetradecanoylphorbol-13-acetate on phenytoin-induced embryopathy in miceToxicology and Applied Pharmacology, 1989
- Modulation of phenytoin teratogenicity and embryonic covalent binding by acetylsalicylic acid, caffeic acid, and α-phenyl-N-t-butylnitrone: Implications for bioactivation by prostaglandin synthetaseToxicology and Applied Pharmacology, 1989
- A high-performance liquid chromatographie assay for reduced and oxidised glutathione in embryonic, neonatal, and adult tissues using a porous graphite electrochemical detectorJournal of Pharmacological Methods, 1988
- Effects of N‐acetylcysteine on fetal development and on phenytoin teratogenicity in miceTeratogenesis, Carcinogenesis, and Mutagenesis, 1988
- Regulation of intracellular glutathione in rat embryos and visceral yolk sacs and its effect on 2-nitrosofluorene-induced malformations in the whole embryo culture systemToxicology and Applied Pharmacology, 1987
- Effects of the long-term depletion of reduced glutathione in mice administered -buthionine-S,R-sulfoximineFundamental and Applied Toxicology, 1985
- Variable patterns of malformation in the mouse fetal hydantoin syndromeAmerican Journal of Medical Genetics, 1984
- New Developments in Glutathione Metabolism and Their Potential Application in TherapyHepatology, 1984
- Toxicologic enhancement by a combination of drugs which deplete hepatic glutathione: Acetaminophen and doxorubicin (Adriamycin)Toxicology and Applied Pharmacology, 1980
- Isolated cleft palate in A/J mice after transitory exposure to drinking‐water deprivation and low humidity in pregnancyTeratology, 1974